Summary
The deamination of dopamine has been studied in seven regions of human brain. Both A and B forms of the enzyme were found to be active towards this substrate. The ratio of activities of MAO-A: MAO-B was found to vary considerably from brain region to brain region, from about 1∶1 for the cerebral and cerebellar cortex to about 1∶2 for the pons and medula oblongata. Enzyme titration studies and comparisons of the substrate specificities of MAO-A and MAO-B across the brain indicated that dopamine was metabolised by the same MAO active centres as other monoamines. In the cerebral cortex, the K m values of MAO-A and-B towards dopamine were found to be 210 and 230 μM, respectively, indicating that the relative contributions of these two forms towards the oxidation of this substrate will not be significantly affected by changes in its concentration.
Similar content being viewed by others
References
Collins GGS, Sandler M, Williams ED, Youdim MBH (1970) Multiple forms of human brain mitochondrial monoamine oxidase. Nature (Lond) 225:817–820
Fowler CJ, Oreland L (1981) Substrate- and stereoselective inhibition of human brain monoamine oxidase by 4-dimethylamino-α,2-dimethylphenethylamine (FLA 336). J Pharm Pharmacol 33:403–406
Fowler CJ, Tipton KF (1982) Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J Neurochem 38:733–736
Fowler CJ, Callingham BA, Mantle TJ, Tipton KF (1978) Monoamine oxidase A and B: a useful concept? Biochem Pharmacol 27: 97–101
Fowler CJ, Callingham BA, O'Connor MDL, Matthews EK (1980a) The effect of sonication upon monoamine oxidase-A and-B in the rat liver. Biochem Pharmacol 29:1185–1188
Fowler CJ, Oreland L, Marcusson J, Winblad B (1980b) Titration of human brain monoamine oxidase-A and-B by clorgyline and l-deprenyl. Naunyn-Schmiedeberg's Arch Pharmacol 311:263–272
Fowler CJ, Wiberg Å, Oreland L, Winblad B (1980c) Titration of human brain type B monoamine oxidase. Neurochem Res 6:697–708
Fowler CJ, Wiberg Å, Oreland L, Marcusson J, Winblad B (1980d) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49:1–20
Garrick NA, Murphy DL (1981) Differences in the preferential deamination of l-norepinephrine, dopamine and serotonin by MAO in rodent and primate brains. In: Usdin E, Weiner N, Youdim MBH (eds) Function and regulation of monoamine enzymes. Basic and clinical aspects. Macmillan, London, pp 517–525
Glover V, Elsworth JD, Sandler M (1980) Dopamine oxidation and its inhibition by (-)-deprenyl in man. J Neural Transm Suppl 16: 163–172
Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature (Lond) 265:80–81
Green AR, Mitchell BD, Tordoff AFC, Youdim MBH (1977) Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 60:343–349
Hall DWR, Logan BW, Parsons GH (1969) Further studies on the inhibition of monoamine oxidase by M & B 9302 (clorgyline). I. Substrate specificity in various mammalian species. Biochem Pharmacol 18:1447–1454
Houslay MD, Tipton KF (1973) The nature of the electrophoretically separable multiple forms of rat liver monoamine oxidase. Biochem J 135:173–186
Houslay MD, Tipton KF (1974) A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes. Biochem J 139:645–652
Johnston JP (1968) Some observations on a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297
Kinemuchi H, Wakui Y, Kamijo K (1980) Substrate selectivity of type A and type B monoamine oxidase in rat brain. J Neurochem 35:109–115
Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibition. Adv Biochem Psychopharmacol 5: 393–408
MacKay AVP, Davies P, Dewar AJ, Yates CM (1978) Regional distribution of enzymes associated with neurotransmission by monoamines, acetylcholine and GABA in the human brain. J Neurochem 30: 827–839
Markwell MAK, Haas SM, Bieber LL, Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Analyt Biochem 87:206–210
Oreland L, Arai Y, Stenstrom A (1982) MAO in post-mortem brains of psychiatric patients. In: Beckmann H, Riederer P (eds) Monoamine oxidase and its selective inhibitors: New concepts in therapy and research. Karger, Basel (in press)
Otsuka S, Kobayashi Y (1964) A radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem Pharmacol 13: 995–1006
Owen F, Cross AJ, Lofthouse R, Glover V (1979) Distribution and inhibition characteristics of human brain monoamine oxidase. Biochem Pharmacol 28:1077–1080
Riederer P, Reynolds GP, Youdim MBH (1981) Selectivity of MAO inhibition in human brain and their clinical consequences. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors — The state of the act. John Wiley, Chichester, pp 63–76
Robinson DS (1975) Changes in monoamine oxidase and monoamines with human development and aging. Fed Proc 34:103–107
Roth JA (1976) Evidence for a single catalytic binding site on human brain type B monoamine oxidase. J Neurochem 27:1107–1112
Roth JA, Feor K (1978) Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem Pharmacol 27:1606–1608
Suzuki O, Katsumata Y, Oya M (1981a) Oxidation of α-phenethylamine by both types of monoamine oxidase: examination of enzymes in brain and liver mitochondria of eight species. J Neurochem 36:1298–1301
Suzuki O, Katsumata Y, Oya M (1981b) Characterisation of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase. Biochem Pharmacol 30:1353–1358
Tipton KF, Houslay MD, Garrett NJ (1973) Allotopic properties of human brain monoamine oxidase. Nature New Biol (Lond) 246:213–214
Tipton KF, Fowler CJ, Houslay MD (1982) Specificities of the two forms of monoamine oxidase. In: Kamijo K, Usdin E, Nagatsu T (eds) Monoamine oxidase — Basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 87–99
Waldmeier, PC, Maitre L (1975) Lack of significance of MAO-B for the in vivo deamination of dopamine. Naunyn-Schmiedeberg's Arch Pharmacol 287:R2-R3
White HL, Glassman AT (1977) Multiple binding sites of human brain and liver monoamine oxidase: substrate specificities, selective inhibitors, and attempts to separate enzyme forms. J Neurochem 29: 987–997
White HL, Tansik RL (1979) Characterization of multiple substrate binding sites of MAO. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase; structure, function and altered functions. Academic Press, New York, pp 129–144
Youdim MBH, Holman B (1975) The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline. J Neural Transm 37:11–24
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Carroll, AM., Fowler, C.J., Phillips, J.P. et al. The deamination of dopamine by human brain monoamine oxidase. Naunyn-Schmiedeberg's Arch. Pharmacol. 322, 198–202 (1983). https://doi.org/10.1007/BF00500765
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00500765